PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27373854-9	2017	Patients with idiopathic PAH (IPAH) demonstrate increased circulating and tissue levels of OPG, and circulating serum levels predict survival.	ipah	30-34	TNF receptor superfamily member 11b	Homo sapiens	91-94
23130102-0	2012	Altered expression of nuclear and cytoplasmic histone H1 in pulmonary artery and pulmonary artery smooth muscle cells in patients with IPAH.	ipah	135-139	H1.0 linker histone	Homo sapiens	46-56
26869635-8	2016	RESULTS: Gal-3 values were increased in both patients with IPAH (12.2+-0.6 ng/mL; p<0.05) and with PAH-CTD (14.1+-1.6 ng/mL; p<0.05) versus control (8.5+-0.9 ng/mL), while aldosterone was significantly elevated in IPAH only (248.5+-38.8 pg/mL vs control 71.9+-18.2 pg/mL; p<0.05).	ipah	59-63	galectin 3	Homo sapiens	9-14
26869635-8	2016	RESULTS: Gal-3 values were increased in both patients with IPAH (12.2+-0.6 ng/mL; p<0.05) and with PAH-CTD (14.1+-1.6 ng/mL; p<0.05) versus control (8.5+-0.9 ng/mL), while aldosterone was significantly elevated in IPAH only (248.5+-38.8 pg/mL vs control 71.9+-18.2 pg/mL; p<0.05).	ipah	220-224	galectin 3	Homo sapiens	9-14
26869635-11	2016	CONCLUSIONS: Heightened Gal-3 and aldosterone plasma concentrations in PAH patients indicate a role for Gal-3 signalling in the pathobiology of IPAH and PAH-CTD, and may serve as biomarkers for functional status and progression of disease.	ipah	144-148	galectin 3	Homo sapiens	24-29
26869635-11	2016	CONCLUSIONS: Heightened Gal-3 and aldosterone plasma concentrations in PAH patients indicate a role for Gal-3 signalling in the pathobiology of IPAH and PAH-CTD, and may serve as biomarkers for functional status and progression of disease.	ipah	144-148	galectin 3	Homo sapiens	104-109
25218335-6	2014	RESULTS: E-selectin was significantly increased in the IPAH group compared with the other groups [the control, Sch + PH and Sch groups) (p < 0.001) (Fig.	ipah	55-59	selectin E	Homo sapiens	9-19
24446489-1	2014	Idiopathic pulmonary arterial hypertension (PAH [IPAH]) is an insidious and potentially fatal disease linked to a mutation or reduced expression of bone morphogenetic protein receptor 2 (BMPR2).	ipah	49-53	bone morphogenetic protein receptor type 2	Homo sapiens	148-185
24446489-1	2014	Idiopathic pulmonary arterial hypertension (PAH [IPAH]) is an insidious and potentially fatal disease linked to a mutation or reduced expression of bone morphogenetic protein receptor 2 (BMPR2).	ipah	49-53	bone morphogenetic protein receptor type 2	Homo sapiens	187-192
22129439-3	2012	As IPAH is associated with mutations of the bone morphogenetic protein receptor 2 (BMPR2) gene, the aim of this study was to investigate whether this association might also be found in patients with IPH.	ipah	3-7	bone morphogenetic protein receptor type 2	Homo sapiens	44-81
22129439-3	2012	As IPAH is associated with mutations of the bone morphogenetic protein receptor 2 (BMPR2) gene, the aim of this study was to investigate whether this association might also be found in patients with IPH.	ipah	3-7	bone morphogenetic protein receptor type 2	Homo sapiens	83-88
27816994-1	2016	Mutations in the bone morphogenetic protein receptor (BMPR2) gene have been observed in 70 % of patients with heritable pulmonary arterial hypertension (HPAH) and in 11-40 % with idiopathic PAH (IPAH).	ipah	195-199	bone morphogenetic protein receptor type 2	Homo sapiens	54-59
26927848-6	2016	RESULTS: CXCL13 was expressed in pulmonary vascular lesions and lymphocytes of patients with IPAH and inoperable CTEPH, respectively.	ipah	93-97	C-X-C motif chemokine ligand 13	Homo sapiens	9-15
26927848-10	2016	CONCLUSIONS: CXCL13 was overexpressed in pulmonary vascular lesions of patients with IPAH and CTEPH, and increased serum concentrations were found in patients with IPAH and CTEPH, suggesting a potential pathogenic role of CXCL13 in both diseases.	ipah	85-89	C-X-C motif chemokine ligand 13	Homo sapiens	13-19
26927848-10	2016	CONCLUSIONS: CXCL13 was overexpressed in pulmonary vascular lesions of patients with IPAH and CTEPH, and increased serum concentrations were found in patients with IPAH and CTEPH, suggesting a potential pathogenic role of CXCL13 in both diseases.	ipah	164-168	C-X-C motif chemokine ligand 13	Homo sapiens	222-228
23733703-3	2011	In addition, approximately 20% of patients with IPAH carry mutations in BMPR2.	ipah	48-52	bone morphogenetic protein receptor type 2	Homo sapiens	72-77
20096498-2	2010	METHOD: With the aim of increasing the knowledge of these genetic factors in our area, the BMPR2 gene was studied in 17 patients with PAH, 8 with FPAH and 9 with sporadic IPAH.	ipah	171-175	bone morphogenetic protein receptor type 2	Homo sapiens	91-96
22194859-12	2011	In addition we demonstrate C3d deposition in IPAH patients suggesting that complement activation plays a role in the development of PAH in humans.	ipah	45-49	endogenous retrovirus group K member 13	Homo sapiens	27-30
18931051-10	2008	CD133(pos) cells were detected in occlusive lesions and perivascular areas in those with PAH and were more numerous in those with IPAH lesions than in FPAH lesions.	ipah	130-134	prominin 1	Homo sapiens	0-5
19403296-1	2009	BACKGROUND: Although previous studies have shown that peripheral airway obstruction can occur in idiopathic PAH (IPAH), pulmonary function tests have not been well-studied in patients with PAH associated with congenital heart disease (CHD-PAH) and connective tissue disease (CTD-PAH).	ipah	113-117	phenylalanine hydroxylase	Homo sapiens	108-111
19555857-3	2009	In addition, approximately 20% of patients with IPAH carry mutations in BMPR2.	ipah	48-52	bone morphogenetic protein receptor type 2	Homo sapiens	72-77
18322242-6	2008	In a murine model, Shigella strains expressing YopE(50)-IL-10, IpaH(60)-IL-10, and IpaH(60)-IL-1ra induced a lower mortality in mice that was associated with reduced inflammation and a restricted localization of bacteria within the lung tissues as compared with wild-type Shigella.	ipah	83-87	interleukin 1 receptor antagonist	Mus musculus	92-98
17003842-3	2007	Our group correlated a deficiency in vasoactive intestinal peptide (VIP; MIM# 192320) levels in serum and lung tissue with the pathogenesis of IPAH.	ipah	143-147	vasoactive intestinal peptide	Homo sapiens	68-71
18322242-4	2008	YopE(50)-IL-10, IpaH(60)-IL-10, and IpaH(60)-IL-1ra were efficiently secreted via the T3S apparatus of Shigella.	ipah	36-40	interleukin 1 receptor antagonist	Mus musculus	45-51
11418613-9	2001	The nuclear transport of IpaH(9.8) does not depend on host cytosolic factors but is partially dependent on ATP/GTP, suggesting that, like beta-catenin, IpaH(9.8) secreted from intracellular Shigella can be transported into the nucleus.	ipah	25-29	catenin beta 1	Homo sapiens	138-150
11418613-9	2001	The nuclear transport of IpaH(9.8) does not depend on host cytosolic factors but is partially dependent on ATP/GTP, suggesting that, like beta-catenin, IpaH(9.8) secreted from intracellular Shigella can be transported into the nucleus.	ipah	152-156	catenin beta 1	Homo sapiens	138-150
2431946-3	1986	Our previous reports have shown that lobuloalveolar development, induced by IPAH, is competitively inhibited by the simultaneous presence of dibutyryl cyclic AMP (Bt2cAMP), prostaglandins (PGs) E1, E2, and B1, and papaverine (pap).	ipah	76-80	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	198-208
33971060-6	2021	In IPAH group, PVR and mPAP were correlated significantly with the perfusion measurements at SCP and DCP (r =0.461, r =0.626 and r =0.625, r =0.730, respectively, P <0.05).	ipah	3-7	phospholipid phosphatase 1	Mus musculus	23-27
33971060-6	2021	In IPAH group, PVR and mPAP were correlated significantly with the perfusion measurements at SCP and DCP (r =0.461, r =0.626 and r =0.625, r =0.730, respectively, P <0.05).	ipah	3-7	urocortin 3	Homo sapiens	93-96
32337710-8	2020	ADGRG6/GPR126, an adhesion GPCR, was increased in IPAH-PASMCs compared to control-PASMCs.	ipah	50-54	adhesion G protein-coupled receptor G6	Homo sapiens	0-6
32337710-8	2020	ADGRG6/GPR126, an adhesion GPCR, was increased in IPAH-PASMCs compared to control-PASMCs.	ipah	50-54	adhesion G protein-coupled receptor G6	Homo sapiens	7-13
28461778-9	2017	We suggest that, VDAC1 has a protective role in PAH and the gene expression signature of VDAC1 influenced genes can be used to i) predict severity of pulmonary hypertension secondary to pulmonary diseases, ii) differentiate idiopathic pulmonary artery hypertension (IPAH) patients from controls, and iii) differentiate IPAH from connective tissue disease associated PAH.	ipah	266-270	voltage dependent anion channel 1	Homo sapiens	17-22
30218748-8	2019	There were also associations of the SERT L/S polymorphism with IPAH and PAH in COPD [IPAH L/S: OR = 1.26, 95% CI, 1.01-1.57; PAH in COPD L/S: OR = 1.42, 95% CI, 1.04-1.94].	ipah	63-67	solute carrier family 6 member 4	Homo sapiens	36-40
30218748-12	2019	Moreover, L allele in 5-HTT gene increased susceptibility to IPAH and PAH in COPD.	ipah	61-65	solute carrier family 6 member 4	Homo sapiens	22-27
30054359-10	2018	The kcat and Km of IpaH against iprodione were 22.42 s-1 and 7.33 muM, respectively, and the catalytic efficiency value (kcat/Km ) was 3.09 muM-1 s-1 IpaH has a Ser-Ser-Lys motif, which is conserved among members of the amidase signature family.	ipah	19-23	amidase	Bradyrhizobium diazoefficiens USDA 110	220-227
28461778-9	2017	We suggest that, VDAC1 has a protective role in PAH and the gene expression signature of VDAC1 influenced genes can be used to i) predict severity of pulmonary hypertension secondary to pulmonary diseases, ii) differentiate idiopathic pulmonary artery hypertension (IPAH) patients from controls, and iii) differentiate IPAH from connective tissue disease associated PAH.	ipah	266-270	voltage dependent anion channel 1	Homo sapiens	89-94